prednisone + ustekinumab

Prednisone + ustekinumab is a combination therapy consisting of two distinct agents used primarily in the management of autoimmune and inflammatory diseases. Prednisone is a synthetic glucocorticoid corticosteroid that exerts broad anti-inflammatory and immunosuppressive effects by modulating gene expression, reducing cytokine production, and inhibiting multiple immune cell functions. Ustekinumab is a fully human monoclonal antibody targeting the p40 subunit shared by interleukin-12 (IL-12) and interleukin-23 (IL-23), thereby inhibiting their signaling pathways involved in inflammatory processes. This combination has been studied in conditions such as giant cell arteritis (GCA) and Crohn’s disease, typically when rapid control of inflammation is needed or when monotherapy has proven insufficient[1][2][4]. However, clinical evidence suggests that combining these drugs may not always improve outcomes compared to monotherapy with either agent[1][6].